KURA (Kura Oncology) EBITDA Margin %: -397.67% (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Kura Oncology Inc KURA

What is Kura Oncology EBITDA Margin %?

Kura Oncology KURA -4.63% 28 EBITDA Margin % is -397.67% as of Mar. 2026. GuruFocus rates KURA with a GF Score™ of 28/100. The stock has 7 warning signs investors should review. Among 939 Biotechnology companies, Kura Oncology ranks worse than 69.54% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kura Oncology's EBITDA for the three months ended in Mar. 2026 was $-72.63 Mil. Kura Oncology's Revenue for the three months ended in Mar. 2026 was $18.27 Mil. Therefore, Kura Oncology's EBITDA margin for the quarter that ended in Mar. 2026 was -397.67%.

Kura Oncology (NAS:KURA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Kura Oncology EBITDA Margin % Related Terms

Kura Oncology EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Kura Oncology's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kura Oncology EBITDA Margin % Chart

Kura Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

-314.57

-408.74

Kura Oncology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															-401.05	-428.49	-354.50	-462.50	-397.67

KURA vs REPL, AVTX, SANA: EBITDA Margin % Comparison

For the Biotechnology subindustry, Kura Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kura Oncology EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kura Oncology's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Kura Oncology's EBITDA Margin % falls into.

Save Embed

28GF Score

Kura Oncology Inc KURA

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Kura Oncology EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Kura Oncology's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-275.825	/	67.482
	=	-408.74 %

Kura Oncology's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-72.634	/	18.265
	=	-397.67 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -397.67% mean?

Kura Oncology (KURA) has a EBITDA Margin % of -397.67% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kura Oncology and its competitors. According to the industry distribution chart, Kura Oncology ranks #653 out of 939 companies in the Biotechnology industry, placing it in the top 69.5%.

Is Kura Oncology's EBITDA Margin % too high?

Kura Oncology's current EBITDA Margin % is -397.67%. Based on the distribution chart, Kura Oncology ranks #653 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kura Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Kura Oncology's EBITDA Margin % compare to REPL and AVTX?

According to the Biotechnology industry distribution chart, Kura Oncology ranks #653 out of 939 companies for EBITDA Margin %. This places Kura Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kura Oncology and its competitors. Kura Oncology's current EBITDA Margin % is -397.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Kura Oncology stock overvalued right now?

Kura Oncology (KURA) has a current EBITDA Margin % of -397.67%. The current EBITDA Margin % is -397.67%. Kura Oncology's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Kura Oncology (KURA), the current EBITDA Margin % is -397.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kura Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies REPL AVTX SANA ANRO ORIC DRTS OLMA LBRX MRVI SLDB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges KUR:Germany

Address 4930 Directors Place, Suite 500, San Diego, CA, USA, 92121

Website https://www.kuraoncology.com

Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.

28GF Score

Get the complete analysis for KURA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.91

Price

View KURA Analysis

See EBITDA Margin % data for all stocks →